Reuters logo
a month ago
BRIEF-TG Therapeutics provides additional data from early-stage cancer drug study
June 15, 2017 / 1:41 PM / a month ago

BRIEF-TG Therapeutics provides additional data from early-stage cancer drug study

1 Min Read

June 15 (Reuters) - TG Therapeutics Inc

* Tg therapeutics - triple combination of tg-1101, tgr-1202 and bendamustine was generally well-tolerated with only gr 3/4 event >10% being neutropenia

* Announces follow-up data from triple combination of tg-1101, tgr-1202, and bendamustine in patients with dlbcl and fl

* 100% orr, including 50% cr rate in patients with relapsed diffuse large b-cell lymphoma (dlbcl) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below